Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab sequential therapy after chemoradiation for locally advanced unresected head and neck squamous cell carcinoma
2023-508613-17-00Phase 3Authorised
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Dostarlimab sequential therapy with Placebo sequential therapy (2 arms). Primary endpoint: Event-free survival by blinded independent central review. Planned start May 2024; status: authorised.
02
Drugs
dostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-508613-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508613-17-00.